Who Owns Evotec Company?

Evotec Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Evotec?

Understanding Evotec's ownership is key to grasping its strategic path and operational influence. The company's dual listing on NASDAQ in November 2021, alongside its Frankfurt Stock Exchange presence, expanded its investor reach and capital access for growth.

Evotec SE, founded in Hamburg, Germany in 1993, is a global drug discovery and development firm. It aims to speed up the creation of new medicines through collaborations, offering services from target identification to clinical development, utilizing proprietary platforms and expertise in areas like oncology and neurology.

As of December 31, 2024, Evotec reported revenues of €797.0 million. Its market capitalization was €7.5 billion as of December 31, 2021, with over 4,200 employees globally in 2021. The company's business model includes fee-for-service and milestone/royalty payments, supported by tools like the Evotec BCG Matrix.

Evotec SE's journey began in 1993 in Hamburg, Germany, with a founding team comprising scientists and entrepreneurs. This group included notable figures such as Dr. Karsten Henco, Professor Dr. Klaus Breddin, and Nobel Laureate Manfred Eigen. The company's early days saw funding from venture capital and initial investors, though specific equity details from its inception are not publicly disclosed.

Founding Vision

The core mission from the outset was to establish Evotec as a premier partner in drug discovery.

Early Public Offering

Evotec BioSystems, its original name, became publicly traded in 1999 on the Frankfurt Stock Exchange.

Merger and Expansion

A significant development occurred in 2000 with the merger with Oxford Asymmetry International plc.

Name Change

Following the merger, the company adopted the name Evotec OAI, broadening its expertise.

Capital for Growth

The initial public offering was instrumental in securing capital for the company's expansion efforts.

Strategic Evolution

The company's strategic direction has consistently been shaped by its foundational goal of drug discovery partnership.

The company's transition to a public entity through its 1999 IPO on the Frankfurt Stock Exchange under the ticker EVT marked a pivotal moment, providing essential capital for growth and enhancing its market presence. This was followed by a strategic merger in 2000 with Oxford Asymmetry International plc, a UK-based chemical services firm. This integration led to the adoption of the Evotec OAI name and significantly expanded its capabilities in medicinal chemistry and early-stage drug development. While specific details regarding early shareholder agreements, such as vesting schedules or buy-sell clauses, are not publicly available, the company's foundational objective to become a leading drug discovery partner has remained a guiding principle throughout its evolution. Understanding Evotec ownership today requires looking beyond these early stages to its current publicly traded status. For a deeper dive into the competitive landscape, you can explore the Competitors Landscape of Evotec.

Key Milestones in Evotec's Early History

Evotec's formative years were characterized by strategic moves aimed at building its capabilities and market position.

• Founding in Hamburg, Germany, in 1993 by a team of scientists and entrepreneurs.
• Initial funding secured from venture capital and early-stage investors.
• Initial Public Offering (IPO) in 1999 on the Frankfurt Stock Exchange (EVT).
• Merger with Oxford Asymmetry International plc in 2000, leading to the name Evotec OAI.
• Expansion of services into medicinal chemistry and early-stage drug development.
• Foundational vision to be a leading drug discovery partner.

Evotec SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Evotec SE's ownership journey includes its 1999 Frankfurt Stock Exchange debut and a significant NASDAQ listing in November 2021. This dual listing aimed to bolster its biologics manufacturing capabilities, raising approximately $500 million.

The evolution of Evotec's ownership structure, particularly the increased institutional investment following its NASDAQ listing, has been instrumental in enhancing its access to capital and global recognition. This strategic move supports its expansion in biologics development and manufacturing, a segment that saw substantial growth. The company's financial performance reflects these strategic investments, with revenue increasing by 2% to €797.0 million in fiscal year 2024, and its Just - Evotec Biologics segment experiencing a 71% year-over-year surge to €185.6 million, highlighting the positive impact of these developments on its Revenue Streams & Business Model of Evotec.

Evotec's Shareholder Landscape

Evotec's ownership is primarily characterized by a significant free float, indicating broad public participation. Major stakeholders and institutional investors play a crucial role in its shareholder base.

• Evotec is a publicly traded company, listed on both the Frankfurt Stock Exchange and NASDAQ.
• As of June 2025, approximately 75% of Evotec's shares are in free float.
• Key major shareholders include Novo Holdings A/S, Mubadala Investment Company, and Triton GP HoldCo SARL.
• Institutional investors collectively held around 2.57% of Evotec's NASDAQ-listed stock as of March 31, 2025.
• Notable institutional investors include Mubadala Investment Co PJSC, Wellington Management Group Llp, and BlackRock, Inc.

Evotec PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Evotec SE's governance structure is defined by a two-tier board system, comprising a Management Board and a Supervisory Board, a common framework in German corporate law. The Management Board handles daily operations and external representation, while the Supervisory Board oversees management and appoints its members, without engaging in operational decisions.

Evotec SE adheres to a 'one-share-one-vote' principle, ensuring that each share carries equal voting power at the Annual General Meeting. Shareholders can exercise their rights through electronic postal votes or by appointing proxies, with provisions for virtual meetings allowing electronic participation and voting. Resolutions are typically passed with a simple majority of votes cast and, when necessary, a simple majority of the represented share capital. The company does not have special voting rights, golden shares, or founder shares that would grant disproportionate control. As of June 3, 2025, approximately 46.45% of the registered share capital was represented at the Annual General Meeting, where most management proposals were approved. While Camilla Macapili Languille, Head of Life Sciences at Mubadala Investment Company, serves as an independent Supervisory Board member, Mubadala Investment Company holds about 7% of Evotec SE's voting shares, indicating a significant interest. Understanding these ownership dynamics is crucial for assessing Evotec ownership and who owns Evotec.

Shareholder Voting Power

Evotec SE's voting structure is designed for equitable shareholder representation. Each share grants one vote, and shareholders have flexible options for participation.

• One-share-one-vote principle ensures fairness.
• Shareholders can vote via electronic postal votes or proxies.
• Virtual general meetings facilitate electronic participation.
• Resolutions require a simple majority of votes cast.
• Mubadala Investment Company holds approximately 7% of voting shares.

Evotec Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Evotec SE has undergone significant shifts in its ownership landscape and strategic direction over the past three to five years. These changes include a NASDAQ listing, key leadership transitions, and a strategic refocusing program, all of which influence its current Evotec ownership structure.

The company's recent developments, including leadership changes and a strategic 'Priority Reset' program, are designed to optimize operations and enhance financial performance. These initiatives are occurring against a backdrop of sustained institutional investor interest, indicating confidence in the company's future trajectory within the biopharmaceutical sector.

Leadership Transitions

Key leadership roles have seen changes in early 2024 and late 2024, with new CEOs and business officers taking the helm. These transitions are part of a broader organizational simplification effort.

Strategic Realignment

Evotec's 'Priority Reset' program aims to streamline its structure and boost earnings by at least €40 million annually. This strategic pivot is crucial for its future growth and operational efficiency.

Financial Outlook

For fiscal year 2024, total revenues reached €797.0 million, with a significant 71% surge in the Just - Evotec Biologics segment. The company projects 2025 revenues between €840-880 million.

Divestment of Biologics Unit

A non-binding agreement with Sandoz AG for the potential sale of Just - Evotec Biologics EU for approximately US$300 million was announced on July 30, 2025. This move shifts Evotec towards a technology provider model.

Evotec Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔